JOP20200039A1 - مُستحضر صيدلي يشتمل على hcg مأشوب - Google Patents

مُستحضر صيدلي يشتمل على hcg مأشوب

Info

Publication number
JOP20200039A1
JOP20200039A1 JOP/2020/0039A JOP20200039A JOP20200039A1 JO P20200039 A1 JOP20200039 A1 JO P20200039A1 JO P20200039 A JOP20200039 A JO P20200039A JO P20200039 A1 JOP20200039 A1 JO P20200039A1
Authority
JO
Jordan
Prior art keywords
pharmaceutical preparation
preparation containing
containing recombinant
recombinant hcg
hcg
Prior art date
Application number
JOP/2020/0039A
Other languages
Arabic (ar)
English (en)
Inventor
Cottingham Ian
Plaksin Daniel
Boyd White Richard
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of JOP20200039A1 publication Critical patent/JOP20200039A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JOP/2020/0039A 2009-10-05 2020-02-17 مُستحضر صيدلي يشتمل على hcg مأشوب JOP20200039A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05

Publications (1)

Publication Number Publication Date
JOP20200039A1 true JOP20200039A1 (ar) 2022-10-30

Family

ID=41471027

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0039A JOP20200039A1 (ar) 2009-10-05 2020-02-17 مُستحضر صيدلي يشتمل على hcg مأشوب

Country Status (25)

Country Link
US (5) US8975226B2 (index.php)
EP (2) EP2486051B1 (index.php)
JP (6) JP6176924B2 (index.php)
KR (7) KR20230012104A (index.php)
CN (1) CN107050434B (index.php)
AR (2) AR079876A1 (index.php)
AU (1) AU2010304922B2 (index.php)
BR (1) BR112012007990A2 (index.php)
CA (1) CA2776790A1 (index.php)
DK (1) DK2486051T3 (index.php)
ES (2) ES3036152T3 (index.php)
HR (1) HRP20200941T1 (index.php)
HU (1) HUE050793T2 (index.php)
IL (3) IL218548A (index.php)
IN (1) IN2012DN02073A (index.php)
JO (1) JOP20200039A1 (index.php)
LT (1) LT2486051T (index.php)
MX (1) MX2012003951A (index.php)
PL (1) PL2486051T3 (index.php)
PT (1) PT2486051T (index.php)
RS (1) RS60413B1 (index.php)
RU (2) RU2724528C2 (index.php)
SI (1) SI2486051T1 (index.php)
TW (2) TWI532495B (index.php)
WO (1) WO2011042688A1 (index.php)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
AR090095A1 (es) * 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
ES2784510T3 (es) 2012-12-10 2020-09-28 Seikagaku Kogyo Co Ltd Método para producir un nuevo Factor C recombinante, método para mitigar la inhibición de la reacción en ensayos de endotoxina, y método para medir endotoxina
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
MX389908B (es) * 2015-04-24 2025-03-20 Ferring Bv Metodo de produccion de gonadotrofina.
MY179524A (en) 2015-06-26 2020-11-10 Ferring Bv Methods of purification and/or viral inactivation
HUE071268T2 (hu) * 2018-04-30 2025-08-28 Ferring Bv Készítmény szabályozott petefészek-stimuláláshoz
IL295278A (en) * 2020-02-05 2022-10-01 Novartis Ag cho cell expressing heterodimers of il-15
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) * 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE69524456T2 (de) * 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
ES2268781T3 (es) 1997-06-25 2007-03-16 Applied Research Systems Ars Holding N.V. Analogos de hormonas glicoproteinicas reticuladas con disulfuro, su preparacion y uso.
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US7304031B2 (en) * 2001-10-29 2007-12-04 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
HK1045261A1 (zh) 1999-05-07 2002-11-22 Laboratoires Serono S.A. 促性腺激素
ME00296B (me) 2000-02-22 2011-05-10 Applied Res Systems Ars Holding N V PROCES PREČIŠĆAVANJA hCG I REKOMBINANTNOG hCG PREČIŠĆENOG TOM METODOM
MXPA04002256A (es) 2001-09-12 2004-07-23 Applied Research Systems Uso de gonadotropina corionica humana (gch) en hiperestimulacion ovarica controlada.
PL369606A1 (en) * 2001-10-22 2005-05-02 Applied Research Systems Ars Holding N.V. Gonadotrophins for folliculogenesis
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
MXPA05010773A (es) * 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
US8017388B2 (en) * 2003-08-18 2011-09-13 Glycotope Gmbh Tumour cell lines and uses thereof
ES2350298T3 (es) * 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
CN103627670B (zh) * 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
KR20070110902A (ko) * 2005-03-11 2007-11-20 프레제니우스 카비 도이치란트 게엠베하 비활성 출발 물질로부터 생물활성 당단백질의 생산
WO2007022206A1 (en) * 2005-08-15 2007-02-22 Siemens Vdo Automotive Corporation Automotive diesel exhaust hc dosing valve
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
WO2008011633A2 (en) * 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
TWI488640B (zh) * 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) * 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
CN102549011A (zh) 2012-07-04
ES3036152T3 (en) 2025-09-15
JP2021176867A (ja) 2021-11-11
US11292824B2 (en) 2022-04-05
IL250733A0 (en) 2017-04-30
US20130023476A1 (en) 2013-01-24
KR20210014767A (ko) 2021-02-09
RU2724528C2 (ru) 2020-06-23
RU2588650C2 (ru) 2016-07-10
KR101804479B1 (ko) 2017-12-05
US20180030107A1 (en) 2018-02-01
JP6580104B2 (ja) 2019-09-25
IL218548A0 (en) 2012-05-31
PL2486051T3 (pl) 2020-09-07
LT2486051T (lt) 2020-07-10
EP2486051B1 (en) 2020-03-25
US8975226B2 (en) 2015-03-10
BR112012007990A2 (pt) 2017-07-25
EP3611185B1 (en) 2025-04-30
EP2486051A1 (en) 2012-08-15
US10526390B2 (en) 2020-01-07
SI2486051T1 (sl) 2020-08-31
KR102489143B1 (ko) 2023-01-13
JP2023075144A (ja) 2023-05-30
TWI532495B (zh) 2016-05-11
IL218548A (en) 2017-03-30
TW201632198A (zh) 2016-09-16
JP7196244B2 (ja) 2022-12-26
RU2016118236A3 (index.php) 2019-09-18
AU2010304922B2 (en) 2014-11-06
AR079876A1 (es) 2012-02-29
RS60413B1 (sr) 2020-07-31
IN2012DN02073A (index.php) 2015-08-21
RU2012112907A (ru) 2013-11-10
US20140249082A1 (en) 2014-09-04
HRP20200941T1 (hr) 2020-09-18
JP2016074680A (ja) 2016-05-12
MX2012003951A (es) 2012-05-29
CN107050434B (zh) 2021-07-27
WO2011042688A1 (en) 2011-04-14
KR20190028823A (ko) 2019-03-19
CN107050434A (zh) 2017-08-18
RU2016118236A (ru) 2018-10-29
ES2798258T3 (es) 2020-12-10
DK2486051T3 (da) 2020-06-22
JP6310440B2 (ja) 2018-04-11
PT2486051T (pt) 2020-06-17
AR125991A2 (es) 2023-08-30
US20200247863A1 (en) 2020-08-06
JP7292153B2 (ja) 2023-06-16
KR102213154B1 (ko) 2021-02-05
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
EP3611185A1 (en) 2020-02-19
KR20210141771A (ko) 2021-11-23
TW201113030A (en) 2011-04-16
US20220340634A1 (en) 2022-10-27
KR101987982B1 (ko) 2019-06-11
JP2020000246A (ja) 2020-01-09
US12234272B2 (en) 2025-02-25
CA2776790A1 (en) 2011-04-14
HUE050793T2 (hu) 2021-01-28
JP2013506708A (ja) 2013-02-28
KR20230012104A (ko) 2023-01-25
KR20170133531A (ko) 2017-12-05
AU2010304922A1 (en) 2012-03-29
IL267556A (en) 2019-08-29
US9676835B2 (en) 2017-06-13
KR20190067256A (ko) 2019-06-14
JP2018076296A (ja) 2018-05-17
JP6176924B2 (ja) 2017-08-09
IL250733B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
JOP20180102B1 (ar) مركب صيدلاني
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX393345B (es) Composiciones farmaceuticas de moduladores c-met.
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
HRP20160807T1 (hr) Visoko koncentrirane farmaceutske formulacije koje sadrže protutijelo anti-cd20
PH12013500360B1 (en) Pesticidal compositions
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
IL236315A (en) Compositions comprising purified recombinant iduronate-2-sulfatase
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
BR112013019687A2 (pt) antraquinona contendo preparações/formulações de lignina.
EA201300733A1 (ru) Рекомбинантные микобактерии в качестве вакцины
PT2668959E (pt) Compostos imunogénicos compreendendo o péptido gp41 do vih acoplado à proteína transportadora crm197
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
TR201100148A2 (tr) Stabil akarboz förmülasyonları.
MX2015012905A (es) Formulaciones de factor viii recombinantes.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
TR201007106A1 (tr) Sefpodoksim proksetil formülasyonları.
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
TR201009168A2 (tr) Suda dağılan sefpodoksim proksetil formülasyonları.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX2012007097A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.